72 episodes

Twice monthly (aspirational) recap of the NephJC journal club. NephJC reviews the most important manuscripts which are driving nephrology forward and improving our understanding of the kidney.

Freely Filtered, a NephJC Podcast NephJC

    • Health & Fitness

Twice monthly (aspirational) recap of the NephJC journal club. NephJC reviews the most important manuscripts which are driving nephrology forward and improving our understanding of the kidney.

    FF 72: Nefecon for IgAN, The NefIgArd part B trial

    FF 72: Nefecon for IgAN, The NefIgArd part B trial

    Nefecon, coated budesonide, is the first drug labelled for IgA nephropathy and the approval path, 9-month reduction in proteinuria followed by 2 year GFR data set the stage for the GN renaissance we are currently living through.

    • 1 hr 32 min
    FF 71: Semaglutide for diabetic nephropathy FLOW

    FF 71: Semaglutide for diabetic nephropathy FLOW

    On May 24th, at the ERA meeting in Stockholm Sweden (this will not be the last GLP1ra talk at Stockholm), Vlado Perkovic presented the previously spoiled results of FLOW. In addition to simultaneous publication in the NEJM, it made the front page in newspapers around the world. As one headline writer said, “Is there anything Ozempic can’t do?”

    • 1 hr 23 min
    FF 70: The PRAECIS trial, predicting severe preeclampsia

    FF 70: The PRAECIS trial, predicting severe preeclampsia

    Nothing terrifies nephrologists, quite like the consult from labor and delivery. And one of the most vexing questions is, “Is this preeclampsia or proteinuric CKD or a lupus flare?” Perhaps a newly approved blood test will be able to shed light on this clinical conundrum. The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) has appeared predictive of severe preeclampsia. The PRAECIS trial evaluated this is a prospective manner.

    Join the filtrate as we do a truly incompetent job discussing this study.

    • 1 hr 16 min
    FF 69:DUPLEX Sparsentan, it’s no Acthar Gel

    FF 69:DUPLEX Sparsentan, it’s no Acthar Gel

    FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?

    • 1 hr 41 min
    FF 68: Inpatient hypertension

    FF 68: Inpatient hypertension

    Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something.

    No. The answer is no.

    But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine.

    Stop it. Just stop it.

    Join the filtrate as we dissect a recent study looking at this issue with the lead author.

    • 1 hr 28 min
    FF67: NephMadness Animal House

    FF67: NephMadness Animal House

    NephMadness prides itself on not repeating topics. Most topics don’t get revisited for years after a single appearance. But one region stands alone. One region is making its fourth appearance in the 12 year history of NephMadness! That region is Animal House!

    Modern medical education doesn’t go to the comparative physiology well very often. So when we do, it is always fresh and exciting. Join the Filtrate as we explore the fascinating world of the Gila Monster and Mourning Dove.

    • 47 min

Top Podcasts In Health & Fitness

On Purpose with Jay Shetty
iHeartPodcasts
The Psychology of your 20s
iHeartPodcasts
Huberman Lab
Scicomm Media
Kabasho
Hamda Hussein
The School of Greatness
Lewis Howes
The Mindset Mentor
Rob Dial

You Might Also Like

The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
Core IM | Internal Medicine Podcast
Core IM Team
Channel Your Enthusiasm
Channel Your Enthusiasm
The Curious Clinicians
The Curious Clinicians
Annals On Call Podcast
American College of Physicians
Cardionerds: A Cardiology Podcast
CardioNerds